Previous 10 | Next 10 |
Compugen to Present at the Cantor Global Healthcare Conference PR Newswire HOLON, Israel , Sept. 14, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today...
Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference PR Newswire HOLON, Israel , Aug. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer i...
Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development - Phase 1/2 clinical study will evaluate AZD2936, a TIGIT/PD-1 bispecific antibody of AstraZeneca, in non-small cell lung cancer - COM902, Compugen's high affinity anti-TIGIT antibody wa...
Shares of Compugen (NASDAQ: CGEN) were rising 4% as of 11:05 a.m. EDT on Thursday. This marked the second consecutive day of solid gains for the stock. The drugmaker's shares jumped on Wednesday after Compugen provided its second-quarter update. There wasn't any news today, thou...
Image source: The Motley Fool. Compugen Ltd (NASDAQ: CGEN) Q2 2021 Earnings Call Jul 28, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Compugen Ltd (CGEN) Q2 2021 Earnings Call Transcript
Compugen Ltd (CGEN) Q2 2021 Earnings Conference Call July 28, 2021, 08:30 ET Company Participants Yvonne Naughton - Head, Investor Relations & Corporate Communication. Anat Cohen-Dayag - CEO, President & Director Ari Krashin - Chief Financial & Operating Officer Eran Ophir - VP, R...
Compugen shares rise ([[CGEN]] +6.3%) after the company posted second quarter results and talked up its cash position.The company highlighted that it had no debt and said that, as of June 30, 2021, cash, cash related accounts, short-term and long-term bank deposits totaled ~$111M, vs ~$124M o...
[[ADP]],[[ALKS]],[[AMG]],[[APH]],[[ARCC]],[[AVY]],[[BA]],[[BG]],[[BMY]],[[BXMT]],[[CCJ]],[[CGEN]],[[CHEF]],[[CME]],[[CSTM]],[[DRVN]],[[DT]],[[EEFT]],[[EPD]],[[EVR]],[[EXP]],[[EXTR]],[[GD]],[[GIB]],[[GNRC]],[[GRMN]],[[HES]],[[HUM]],[[IART]],[[INMD]],[[LFUS]],[[LIVN]],[[LNTH]],[[MCD]],[[MCO]],[...
Shares of Compugen Ltd. (NASDAQ:CGEN) traded at a new 52-week low today of $6.55. Approximately 216,000 shares have changed hands today, as compared to an average 30-day volume of 1 million shares. Compugen Ltd. has overhead space with shares priced $6.62, or 0.0% below the average conse...
Compugen (CGEN) announces that the first patient has been dosed in the cohort expansion arm of the Phase 1/2 study evaluating the triple combination of COM701, with Bristol Myers Squibb's Opdivo (nivolumab) and investigational anti-TIGIT antibody, BMS-986207.CGEN shares down 2% premarket...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...